Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AVNW +19.7%, CRTO +14.9%, YUMC +13.6% (also dividend increase; to repurchase $1.25 bln shares in 2024), ENPH +13.3%, AZEK +12.4%, SONO +11.1%, FTNT +9.4%, CRUS +9%, TENB +7.1%, XPO +6.5%, F +6.3% (also supplemental dividend), LUMN +5.9%, ELF +5.5%, KD +5%, NBR +4.6%, REYN +4.2%, WFRD +3.8%, OI +3.7%, CG +3.1%, FRSH +3%, BAM +3%, CMG +2.8%, EMR +2.7%, AIZ +2.5%, AB +2.4%, PFGC +1.8%, AMCR +1.7%, CVS +1.7%, SIMO +1.6%, BG +1.6%, ARI +1.4%, OMC +1.3%, ARCC +1.3%, EXEL +1.2%, AFG +1.1% (also special div of $2.50/sh), RITM +1.1%, UDR +1%, EEFT +1%, BABA +1%, DEI +0.9%
Other news:
- RGNX +12.6% (announces completion of enrollment in cohort 2 and additional positive interim data in AFFINITY DUCHENNE Trial)
- IMAB +11.9% (signs agreement to divest its assets and business operations in China)
- HCM +5.8% (highlights presentation of Phase III data on Fruquintinib in second-line gastric cancer at ASCO Plenary Series Session)
- FOXA +3.8% (Fox WBD and DIS aiming to create new sports centered streaming service)
- JAMF +2.9% (announces support for Apple Vision Pro)
- FREY +2.9% (provides operations and financial update)
- WBD +2.6% (Fox WBD and DIS aiming to create new sports centered streaming service)
- FDMT +2.3% (prices offering of common stock and warrants for gross proceeds of ~$300 mln)
- RRC +1.5% (Q4 production update)
Analyst comments:
- SYM +3.8% (upgraded to Buy from Neutral at DA Davidson)
- TOST +2.8% (upgraded to Buy from Neutral at Redburn Atlantic)
- TGT +1.9% (upgraded to Buy from Hold at Gordon Haskett)
- CCK +1.7% (upgraded to Overweight from Neutral at JP Morgan)
- DLTR +1.3% (upgraded to Buy from Accumulate at Gordon Haskett)
- WST +0.7% (upgraded to Buy from Hold at Jefferies)